Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of LCI699 in Cushing's Disease Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a confirmed diagnosis of Cushing's Disease (persistent or recurrent) as evidenced by increased 24-hour urine free cortisol (UFC), normal or increased morning plasma Adrenocorticotropic Hormone (ACTH), and pituitary origin of excess ACTH.~* Patients with de novo Cushing's disease can be included only if they are not considered candidate for surgery~Exclusion Criteria:~* Patients treated with mitotane 6 months prior to Visit 1~* Patients with compression of the optic chiasm~* Patients with a known inherited syndrome as the cause for hormone over secretion~* Patients with Cushing's syndrome due to ectopic ACTH secretion or adrenal Cushing's syndrome~* Patients with pseudo-Cushing's syndrome~* Patients who are not biochemically euthyroid~* Diabetic patients with poorly controlled diabetes (HbA1c \>9%)~* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 1 week after completion of dosing.~* Patients who have received pituitary irradiation within five years prior to Visit 1.~* Patients with risk factors for QTc prolongation or Torsade de Pointes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Part l: Core cohort (Type: EXPERIMENTAL): Participants took an ascending dose of LCI699 (osilodrostat) from 2mg bid or 5 mg bid, up to 30 mg bid and participated in Part I of this study. 4 patients in this cohort moved to Part II of the study
- Part II Core: Expansion cohort (Type: EXPERIMENTAL): Participants took an ascending dose from 2mg bid or 5 mg bid, up to 30 mg bid and participated in the Part II Core Expansion of this study. These patients were all newly enrolled into the phase II part of the study
- Part II Core: Follow-up cohort (Type: EXPERIMENTAL): Participants took an ascending dose from 2mg bid or 5 mg bid, up to 30 mg bid and participated in the Part II Core Follow-up of this study. These patients were patients who transferred from Part I Core phase of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).